Cero Therapeutics Holdings, Inc. filed an 8-K on February 4, 2026, reporting a poster presentation at the Transplantation and Cellular Therapy Meetings, detailing information intended to be viewed in conjunction with other company filings. This event, while informative, is not deemed significant for equity investors.